It is widely accepted that increasing adiposity is associated with insulin resistance and increased risk of type II diabetes. The predominant paradigm used to explain this link is the portal/visceral hypothesis. This hypothesis proposes that increased adiposity, particularly in the visceral depots, leads to increased free-fatty acid flux and inhibition of insulin-action via Randle's effect in insulin-sensitive tissues. OBJECTIVES: In this review, limitations of this paradigm will be discussed and two other paradigms that may explain established links between adiposity and insulin resistance/diabetes will be presented. (a) Ectopic fat storage syndrome. Three lines of evidence support this concept. Firstly, failure to develop adequate adipose tissue mass (also known as 'lipodystrophy') results in severe insulin resistance and diabetes. This is thought to be the result of ectopic storage of lipid into liver, skeletal muscle and the pancreatic insulin-secreting beta cell. Secondly, most obese patients also shunt lipid into the skeletal muscle, the liver and probably the beta cell. The importance of this finding is exemplified by several studies demonstrating that the degree of lipid infiltration into skeletal muscle and liver highly correlates with insulin resistance. Thirdly, increased fat cell size is highly associated with insulin resistance and the development of diabetes. Increased fat cell size may represent the failure of the adipose tissue mass to expand and therefore to accommodate an increased energy influx. Taken together, these observations support the 'acquired lipodystrophy' hypothesis as a link between adiposity and insulin resistance. Ectopic fat deposition is therefore the result of additive or synergistic effects including increased dietary intake, decreased fat oxidation and impaired adipogenesis. (b) Endocrine paradigm. This concept was developed in parallel with the 'ectopic fat storage syndrome' hypothesis. Adipose tissue secretes a variety of endocrine hormones such as leptin, interleukin-6, angiotensin II, adiponectin and resistin. From this viewpoint, adipose tissue plays a critical role as an endocrine gland, secreting numerous factors with potent effects on the metabolism of distant tissues. CONCLUSIONS: The novel paradigms of ectopic fat and fat cell as an endocrine organ probably will constitute a new framework for the study of the links between our obesigenic environment and the risk of developing diabetes.
In obesity, experimental evidence has confirmed the presence of insulin resistance in adipose tissue, muscle 7 and liver. 8 As a consequence, when obese subjects develop diabetes, there is a weakened inhibition of splanchnic glucose output with simultaneous insulin increase and elevated concentrations of free-fatty acids (FFA). 4 However, the insulin resistance that accompanies obesity is related to a decrease in total body glucose disposal and is thought to occur predominantly in the skeletal muscle. 9 It has been clearly demonstrated that both an increase in fatness and a preferential upper body accumulation of fat are independently related to insulin resistance. 10 Obese women with a greater proportion of upper-body fat (measured by body circumferences) tend to be more insulin resistant, hyperinsulinemic, glucose intolerant and dyslipidemic than obese women with a greater proportion of lower-body fat. 11 When imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT), were used, visceral fat accumulation was found to be specifically associated with the metabolic alterations of obesity, both in men and women. [12] [13] [14] [15] Combined with Randle's hypothesis, [16] [17] [18] the above observations led to the portal hypothesis, which states that the complications of obesity are attributable to increases in visceral adipose tissue with an associated rise in portal vein plasma FFA concentrations. 19 
Failure of the portal hypothesis
While many studies have reported associations between insulin sensitivity and visceral fat mass (reviewed by Kissebah and Krakower 20 ) , associations between the amount of subcutaneous fat on the trunk and insulin resistance have also been reported in obese nondiabetic men 21, 22 and in men with type II diabetes. 17, 23, 24 Thus, subcutaneous fat, which does not drain into the portal vein, must cause insulin resistance by a nonportal mechanism. Similarly, insulin resistance in obese women is best related to overall elevated fat mass, or to an increase in truncal subcutaneous fat mass as measured by the sum of skinfolds 25 or by whole-body MRI. 15 Moreover, insulin resistance is predicted independently by an increased truncal subcutaneous fat mass and an increased amount of visceral fat. 14, 25 The observation that total fat mass and subcutaneous fat mass are important to the insulin resistance syndrome, combined with the growing experimental evidence that does not support the Randle/ portal hypothesis, calls for a change in the scientific paradigm. 26 The two emerging paradigms are (a) the 'ectopic fat storage syndrome' and (b) a view of the adipocyte as an endocrine organ.
Ectopic fat storage and insulin resistance Skeletal muscle fat content in obesity and type II diabetes. The content of triglyceride within skeletal muscle is increased in obesity and in type II diabetes mellitus and is a strong predictor of insulin resistance. 22, 27 Increased intramyocellular lipid (IMCL) is postulated to cause defects in insulin signaling in muscle and liver, reduce insulinstimulated muscle glucose transport activity and glycogen synthesis in muscle and impair suppression of hepatic glucose production. 28 CT or MRI can measure IMCL noninvasively. Kelley et al 29 reported that obese subjects have an accumulation of muscle with attenuation values more than 2 standard deviations below the distribution range of lean muscle. They also found associations between skeletal muscle CT characteristics and adiposity, insulin resistance, oxidative enzymatic capacity of muscle and maximal aerobic capacity. 30, 31 More specifically, in obese individuals, muscle attenuation was a stronger body composition correlate of insulin resistance than either visceral adiposity or overall adiposity. 22 Other studies using 1 H nuclear magnetic resonance have shown that IMCL is a strong determinant of in vivo insulin resistance in humans [32] [33] [34] and is higher in young nondiabetic first-degree relatives of subjects with type II diabetes.
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IMCL can be experimentally regulated. For example, intralipid plus insulin infusion rapidly increases IMCL, 35 high fat feeding for 3 days modestly increases IMCL 35 and weight loss decreases IMCL in parallel with improvements in insulin sensitivity. 36 Paradoxically, intramyocellular lipid is also high in athletes, who are extremely insulin sensitive. 37 Thamer et al 38 examined the relationship between IMCL, aerobic fitness and insulin sensitivity. In this study, adiposity was a weak correlate of IMCL, but insulin sensitivity was not related to the amount of IMCL, unless VO 2 max was also taken into account. The reason for this paradox is not clearly understood and may be related to distribution of lipid within the myocyte or differences in capacity for fat oxidation between trained and untrained subjects. Ectopic storage of fat in the liver is also of pathophysiological importance. Subjects with type II diabetes have significantly higher liver lipid content as compared to fat-, sex-and age matched nondiabetic subjects (unpublished observations). Hepatic fat content measured by spectral nuclear magnetic resonance was also associated with insulin resistance, 39 and fat accumulation in the liver (independently of %fat) is associated with impaired suppression of hepatic glucose production by insulin. Obesity is another ectopic fat storage syndrome. Positive energy balance in our obesigenic environment (see Figure 1 ) produces a pattern similar to lipodystrophy in humans, that is, excess lipid storage in liver 39 and skeletal muscle 30, 48 followed by insulin resistance, glucose intolerance and diabetes. However, in contrast to lipodystrophic patients, adipose tissue stores are adequate or even large in obese patients. These observations suggest that the adipose tissue mass is inadequate to sequester dietary lipid away from liver, skeletal muscle and pancreas. This observation is supported by recent studies investigating the action of thiazolidinediones, which, through activation of PPAR-g, promote differentiation of new fat cells in subcutaneous, but not intraperitoneal, adipose tissue. 49 In vivo, this translates into a gain in subcutaneous, but not intraperitoneal, adipose tissue, 50 and a decrease in lipid infiltration in skeletal muscle and liver. The above observations suggest that drug therapies might be designed to target ectopic fat storage as a strategy to improve insulin action and prevent or reverse diabetes. Figure 2 Sequential model of weight gain and insulin resistance. Adipocytes are derived from pleuripotent stem cell precursors. Individuals with a low capacity for proliferation and/or differentiation of mesenchymal precursors into mature fat-storing adipocytes are susceptible to hypertrophy of the existing adipocytes under conditions of energy and/or fat excess, so common in our modern 'obesigenic' environment. Adipocyte hypertrophy leads to ectopic fat storage, insulin resistance and eventually type II diabetes mellitus. HGP: hepatic glucose production.
Why are fat cells larger in patients with obesity and the metabolic syndrome? As discussed above, the evidence supports the view that large fat cells are indicative of a failure of proliferation and/or differentiation of adipocytes ( Figure 2 ). Adipocytes develop from mesenchymal stem cells via a complex cascade of transcriptional and nontranscriptional events. 56 When proliferation is stopped, mesenchymal stem cells are able to differentiate along several mutually exclusive pathways. 57 A mesenchymal stem cell is able to differentiate into a chondrocyte, osteocyte, tenocyte, or adipocyte depending on the paracrine, endocrine and metabolic milieu (Figure 3 ). 58 The control mechanisms for adipocyte differentiation are complex, but examination of the transcriptional and extracellular signals necessary for stem cell differentiation into a preadipocyte, and from the preadipocyte into a mature fat cell, is being elucidated. 59 The mouse cell line 3T3-L1 is the most commonly studied cell in vitro. These cells are characteristic of the preadipocyte in vivo and can only differentiate into mature lipid-storing adipocytes. Regulation of adipocyte differentiation involves growth arrest and the coordinate activation/inactivation of nuclear transcription factors. 60 These transcription factors then regulate the transcription, translation and/or activation of a variety of genes necessary for lipid storage and insulin sensitivity. ADD/SREB-1, C/EBP-a, -b and -d and PPAR-g are a few of the known transcription factors. 56 result strongly supports the hypothesis that decreased adipocyte differentiation is a mechanism through which insulin resistance develops.
Impaired fat oxidation. An alternative explanation for the increased intracellular lipid is that whole-body fat oxidation is impaired in these subjects, leading to ectopic accumulation of intracellular lipid and insulin resistance. This view holds that the machinery to oxidize fat is not sufficient to match the dietary fat load or is not activated in a timely fashion by a signal (or signals) necessary to oxidize fat. It is also possible that mitochondrial fatty acid availability or transport is decreased. Consistent with the impaired fat oxidation hypothesis, McGarry and co-workers 68 demonstrated that inhibition of fat oxidation in rodents increased intracellular lipid and decreased insulin action in vivo and the two were highly correlated. In humans, previous research has revealed that increased respiratory quotient (indicative of decreased postabsorptive fat oxidation) predicts weight gain [69] [70] [71] and is associated with deterioration of insulin sensitivity. Recently, Perseghin et al 72 examined the association between insulin sensitivity, lipid oxidation and IMCL in young, nonobese subjects above or below a certain percent body fat. In this study, fatter subjects had similar insulin sensitivity and IMCL content as compared to leaner subjects. However, fatter subjects had higher fasting lipid oxidation rates. This suggests that increased fat oxidation is an adaptation to increased body fat that may help maintain normal IMCL concentrations and insulin sensitivity. A large degree of interindividual variability exists in the capacity to oxidize excess dietary fat. 73 Such results are consistent with the 'inadequate fat oxidizing machinery' hypothesis proposed above. Both low aerobic capacity and fasting insulin are highly correlated with the ability to oxidize fat. Fat oxidation capacity can be modulated by exercise training, which increases lipoprotein lipase (LPL), carnitine palmitoyltransferase-I (CPT-I) 74 and the number of mitochondria. 75 Collectively, these processes enhance the availability of FFA, their transport into mitochondria and their rate of oxidation mostly by muscle. Recently, Goodpaster et al 76 showed that 16 weeks of training, in combination with calorie restriction, increased the fasting rate of fat oxidation by 17%. Furthermore, they observed that the strongest predictor of increased insulin sensitivity was the enhanced rate of fat oxidation, accounting for 52% MSCs can differentiate into an osteoblast, a chondroblast, a myocyte and other cell types. These cells are thought to be self-replicating and capable of differentiating into a mature adipocyte. An intermediate cell type, the 'adipiphage', has been proposed. 130 Transcription factors such as SREBP/ ADD, C/EBP-a and -b, PPAR-g and the RXR receptor are important components of the differentiation cascade. Several other regulatory systems include the autocrine/paracrine growth factors, TNF-a, and the Wnt family of proteins. 131 Additional factors that are secreted from the adipocyte and act as autocrine/ paracrine regulators of adipocyte proliferation and differentiation are listed in Figure 4 .
Adiposity, insulin resistance and type II diabetes L Heilbronn et al of the variance in insulin sensitivity. As mentioned earlier, intramuscular lipid stores are associated with maximal aerobic capacity, 30 and physical fitness is associated with the ability to oxidize dietary fat. 73 However, the effects of training on intramyocellular lipid are unclear. Prolonged endurance exercise decreases intramuscular lipid stores in runners. 75 However, Helge and Dela 77 observed that single leg training for 30 min/day in untrained subjects did not alter intramyocellular lipid content, even though glucose uptake was increased after only 8 days of training. Furthermore, in obese and overweight men, 10 weeks of exercise training did not alter intramyocellular lipid levels, although improvements in insulin sensitivity and fat oxidation were observed. 78 These results suggest that exercise-induced improvements in insulin sensitivity occur via an IMCLindependent mechanism. The allosteric regulators of CPT-I (malonyl CoA), and AMP kinase (AMPK), provide minute-to-minute regulation of substrate utilization. In addition to defects in these pathways, individuals with increased intracellular lipid may have inadequate machinery to oxidize an increased flux of fatty acids. In other words, the metabolic signals may be sufficient, but the capacity of the system may be inadequate. Regulation of fuel oxidation may also occur over a longer period through transcriptional or translational regulation of enzymes for fatty acid oxidation. For example, fatty acid transport by CPT-I is regulated not only by malonyl CoA but also by the concentration of CPT-I. CPT-I in turn is regulated in a tissue-specific fashion by the nuclear transcription factors PPAR-a and PPAR-g. [79] [80] [81] Importantly, these two nuclear transcription factors, in concert with the coactivator PGC-1, 82 regulate transcription of the entire repertoire of genes involved in fatty acid oxidation such as ACO. 83, 84 Subjects with diabetes and insulin resistance also have reduced ATP production, evidenced by lower activity of NADH:O 2 oxidoreductase and smaller mitochondrial size as measured by electron microscopy. 85 Reduced mitochondrial capacity may be mediated by peroxisome proliferator activator protein coactivator-1a (PGC-1). 86 PGC-1 is a transcriptional coactivator that is essential for mitochondrial biogenesis and coordinates fiber type switching. PGC-1 is downregulated in type II diabetes. 86, 87 Whether reductions in genes involved in oxidative phosphorylation (OXPHOS) cause diabetes or are an effect of hyperglycemia is currently unknown. However, it is hypothesized that excess nutrients in combination with hyperinsulinemia may mediate activation of the glucosamine pathway, 88 decreasing PGC-1 and other OXPHOS genes, downregulating oxidative phosphorylation. A consequence of this may be downregulation of lipid oxidation and an accumulation of intramyocellular lipid, leading to insulin resistance. Indeed, increased IMCL content has been related to reduced mitochondrial oxidative and phosphorylative activity as assessed by 13 C and 31 P nuclear magnetic resonance. 89 Other neural-endocrine mechanisms may also regulate fat oxidation. Healthy young men treated with a synthetic beta-3 agonist had a reduction in 24-h RQ, 90 indicating an increase in fat oxidation. In addition, infusions of betaadrenergic agonists not only increase energy expenditure but also increase fat oxidation 91, 92 and improve insulin sensitivity. As such, it is possible that the sympathetic nervous system (SNS), acting through the beta-3 adrenoreceptor or other adrenoreceptors, regulates fat oxidation. Importantly, a low SNS activity has been linked to weight gain 93 and decreased fat oxidation, 94 again suggesting the importance of SNS in the regulation of fat oxidation, body weight and insulin sensitivity. Endocrine hormones secreted from the adipocyte or from the neuroendocrine systems may also regulate fat oxidation. For example, adiponectin, leptin and corticotropin-releasing hormone (CRH) have all been shown to increase fat oxidation [95] [96] [97] and will be discussed in more detail below.
An alternate paradigm: the endocrine hypothesis In this model, adipocytes respond to various stimuli to integrate metabolic, hormonal and neural stimuli by releasing hormones (Figure 4) . The molecular revolution brought to light many adipocyte-secreted factors, some of which are secreted into the blood stream such as IL-6, resistin, adiponectin and leptin, 121 whereas others, such as TNF-a, exert their effects in an autocrine -paracrine fashion. Large fat cells, evidence of increased energy influx, are likely to secrete an entirely different pattern of hormones than small adipocytes. For example, adiponectin concentrations are decreased in obesity and type II diabetes. Administration of adiponectin to rodents reduces triglyceride storage in the liver and muscle through AMPKa2 activation. 122 However, the effects of adiponectin in humans are untested. Receptors secreted by the adipocyte is growing rapidly. Several of these proteins/factors act as endocrine hormones, for example, leptin, IL-6, whereas others act locally, for example, TNF-a and the growth factors. The endocrine proteins/factors are proposed to influence distant tissues such as the liver, skeletal muscle or brain to modulate insulin action, that is, the 'endocrine hypothesis'. Paracrine/autocrine factors may also modulate insulin action if they promote or inhibit adipocyte proliferation and/or differentiation. 99, 101, [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [118] [119] [120] [132] [133] [134] [135] Adiposity, insulin resistance and type II diabetes L Heilbronn et al for adiponectin have also recently been identified (AdipoR1 and AdipoR2). In mouse, the AdipoR1 receptor was abundantly expressed in skeletal muscle, whereas AdipoR2 was predominantly expressed in liver. By interfering with RNA expression of both receptors, adiponectin-induced activation of AMPK was blunted, causing an impairment of fatty acid oxidation and glucose uptake. 123 This suggests that a downregulation of both the AdipoR1 and AdipoR2 receptors in skeletal muscle may be involved in the development of insulin resistance. Indeed, adipoR1 and adipoR2 expression was downregulated in nondiabetic insulin-resistant relatives of subjects with type II diabetes as compared to sex-and weight-matched nonrelatives. 124 Leptin also selectively stimulates phosphorylation and activation of AMPKa2 in skeletal muscle suppressing the activity of ACC, thereby stimulating the oxidation of fatty acids. 125 Early activation of AMPK occurs by leptin acting directly on muscle, whereas later activation depends on leptin functioning through the hypothalamic-sympathetic nervous system axis. Thus, altered secretion of proteins from large fat cells may lead to impaired fat oxidation and insulin resistance. Other autocrine, paracrine or endocrine factors remain undiscovered.
An alternate hypothesis to that of the endocrine/paracrine effect of large fat cells on the regulation of insulin sensitivity is that enlarged adipocytes may not have a pathophysiological significance by themselves, but are instead only a manifestation (end organ response) of other unknown pathogenic factors. These factors may lead independently to enlarged adipocytes, insulin resistance and other traits of the metabolic syndrome ( Figure 5 ). Glucocorticoids, growth hormones, IGF-1 and sex steroids (modulated by the neuroendocrine systems) might represent common factors since they all impact both glucose homeostasis and adipocyte size. 126 Neuropeptides such as NPY and AGRP may also influence adipocyte function and endocrine secretion.
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Conclusions
Intramyocellular and intrahepatic lipid deposition are highly associated with insulin resistance. This in conjunction with several emerging flaws in the portal/Randle's hypothesis has led to two alternate paradigms. The first hypothesis, the 'ectopic fat storage syndrome', states that if fat mass cannot expand through the proliferation and differentiation of new adipocytes in times of excess nutrient intake, then adipocyte hypertrophy results and excess dietary fat may be shunted to the liver, skeletal muscle and the beta cell. Importantly, if fat oxidation cannot be increased to compensate for the increased influx of lipid within these tissues, then intracellular accumulation of lipids will occur. A second paradigm, the 'endocrine hypothesis', is based on the growing number of factors that are released from adipocytes, with potent effects on metabolism and insulin sensitivity. In the next decade, these two paradigms probably will constitute a new framework for the study of the links between our obesigenic environment and the risk of developing diabetes. It may also lead to the development of new pharmacological strategies to treat insulin resistance and possibly reduce the rapidly increasing incidence of type II diabetes mellitus. Adiposity, insulin resistance and type II diabetes L Heilbronn et al
